Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance

Helicobacter pyloritherapy: a paradigm shift

(2016) David Y. Graham et al.   Expert Review of Anti-Infective Therapy

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues

(2016) David Y Graham   GUT

Role of bismuth in improvingHelicobacter pylorieradication with triple therapy

(2016) Maria Pina Dore et al.   GUT

Molecular Detection ofH. pyloriUsing Adherent Gastric Mucous to Biopsy Forceps

(2016) Hiroshi Matsumoto et al.   HELICOBACTER

Molecular Approaches to Identify Helicobacter pylori Antimicrobial Resistance

(2015) Francis Mégraud et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Hp-normogram (normo-graham) for Assessing the Outcome ofH. pyloriTherapy: Effect of Resistance, Duration, and CYP2C19 Genotype

(2015) David Y. Graham   HELICOBACTER

New dual therapy for primary treatment ofHelicobacter pyloriinfection: A prospective randomized study in Shanghai, China

(2014) Ling Ren et al.   Journal of Digestive Diseases

Strategies for eliminating death from gastric cancer in Japan

(2014) Masahiro ASAKA et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

The effects of varying acidity onHelicobacter pylorigrowth and the bactericidal efficacy of ampicillin

(2012) E. A. Marcus et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Incidence of Helicobacter pylori infection and their clarithromycin-resistant strains in otitis media with effusion regarding phenotypic and genotypic studies

(2012) Nahla A. Melake et al.   SAUDI PHARMACEUTICAL JOURNAL

Application of stool-PCR for the diagnosis of Helicobacter pylori from stool in Nigeria- a pilot study

(2012) Stella I Smith et al.   SpringerPlus

A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands

(2011) Jun Matsukawa et al.   BIOCHEMICAL PHARMACOLOGY

Efficacy of 2-Week, Second-Line Helicobacter pylori Eradication Therapy Using Rabeprazole, Amoxicillin, and Metronidazole for the Japanese Population

(2011) Kazutoshi Hori et al.   HELICOBACTER

A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals

(2011) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Role of Omeprazole Dosage and Cytochrome P450 2C19 Genotype in Patients Receiving Omeprazole-Amoxicillin Dual Therapy forHelicobacter pyloriEradication

(2011) Jyh-Chin Yang et al.   PHARMACOTHERAPY

Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection

(2010) Takahisa Furuta et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Helicobacter pylori treatment in the era of increasing antibiotic resistance

(2010) D. Y. Graham et al.   GUT

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Long-lasting inhibitors of the gastric H,K-ATPase

(2009) Jai Moo Shin et al.   Expert Review of Clinical Pharmacology

Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH

(2008) Julia Kirchheiner et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

New concepts of resistance in the treatment of Helicobacter pylori infections

(2008) David Y Graham et al.   Nature clinical practice. Gastroenterology & hepatology